Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 285

1. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study Cancers · 2023 · 1 citations
2. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients Supportive Care in Cancer · 2023 · 9 citations
3. Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer 2025
4. Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China BMC Cancer · 2025 · 1 citations
5. Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report Curēus · 2024
6. Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment Patient Preference and Adherence · 2021 · 12 citations
7. Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis Journal of Advanced Research · 2024 · 8 citations
8. Maternal androgen excess inhibits fetal cardiomyocytes proliferation through RB-mediated cell cycle arrest and induces cardiac hypertrophy in adulthood Journal of Endocrinological Investigation · 2023 · 2 citations
9. Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial ESMO Open · 2025 · 2 citations
10. Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer Breast Care · 2021 · 11 citations

Community

— no results